Review Article: Impact of Growth Hormone Treatment on Height in Children with X-Linked Hypophosphatemic Rickets

Munib A. Al-Zubaidi; Wasnaa H. Abdullah

doi:10.32007/jfacmedbaghdad.6632349

المؤلفون

Munib A. Al-Zubaidi Department of Pediatrics, College of Medicine, University of Baghdad, Baghdad, Iraq. https://orcid.org/0000-0001-7078-657X
Wasnaa H. Abdullah Department of Pediatrics, College of Medicine, Al-Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0003-1549-3824

DOI:

https://doi.org/10.32007/jfacmedbaghdad.6632349

الكلمات المفتاحية:

Growth hormone، Rickets، Short stature ، X-linked dominant، X-Linked Hypophosphatemic.

الملخص

الكساح الناقص الفوسفات المرتبط بـ X (XLHR) هو الشكل الأكثر شيوعًا للكساح الموروث. عند الأطفال، غالبًا ما يكون توقف النمو وقصر القامة بشكل غير متناسب من العلامات المبكرة لـ XLHR. قد يستمر تأخر النمو حتى بعد تلقي العلاج التقليدي المناسب (مكملات الفوسفات ونظائرها النشطة من فيتامين د)، حتى لو بدأ في وقت مبكر من مرحلة الطفولة. في الآونة الأخيرة، وبغض النظر عن المرض الذي يتم التحكم فيه جيدًا، تم اقتراح العلاج بهرمون النمو البشري المؤتلف (rhGH) كوسيلة فعالة لدعم النمو لدى الأطفال الذين يعانون من XLHR الذين يظهرون نقصًا في النمو. من الضروري المتابعة حتى الوصول إلى ارتفاع البالغين لتقييم التأثيرات طويلة المدى لعلاج هرمون النمو على الارتفاع النهائي.

التنزيلات

تنزيل البيانات ليس متاحًا بعد.

المراجع

Laurent MR, Harvengt P, Mortier GR, Böckenhauer D. X-linked hypophosphatemia. GeneReviews®[Internet]. 2023 Dec 14. Available from: https://www.ncbi.nlm.nih.gov/books/NBK83985/

André J, Zhukouskaya VV, Lambert AS, Salles JP, Mignot B, Bardet C, et al. Growth hormone treatment improves final height in children with X-linked hypophosphatemia. Orphanet Journal of Rare Diseases. 2022;17(1):1-8.

https://doi.org/10.1186/s13023-022-02590-5 PMid:36544157 PMCid:PMC9768884

Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nature Reviews Nephrology. 2019; 15(7):435-55.

https://doi.org/10.1038/s41581-019-0152-5 PMid:31068690 PMCid:PMC7136170

Cannalire G, Pilloni S, Esposito S, Biasucci G, Di Franco A, Street ME. Alkaline phosphatase in clinical practice in childhood: Focus on rickets. Frontiers in Endocrinology. 2023; 14:1111445. https://doi.org/10.3389/fendo.2023.1111445 PMid: 36817604 PMCid:PMC9931734

Rothenbuhler A, Esterle L, Gueorguieva I, Salles JP, Mignot B, Colle M, et al. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). Growth Hormone & IGF Research. 2017;36:11-5. https://doi.org/10.1016/j.ghir.2017.08.001 PMid: 28822957

Chande S, Bergwitz C. Role of phosphate sensing in bone and mineral metabolism. Nature Reviews Endocrinology. 2018; 14(11):637-55. https://doi.org/10.1038/s41574-018-0076-3 PMid:30218014 PMCid:PMC8607960

Cagnoli M. Spontaneous growth and effect of early therapy with calcitriol and phosphate in X-linked hypophosphatemic rickets. Pediatr Endocrinol Rev. 2017; 17:119-22. https://doi.org/10.17458/per.vol15.2017.crb.spontaneousgrowtheffect

Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity Orphanet Journal of Rare Diseases. 2019;14:1-25. https://doi.org/10.1186/s13023-019-1014-8 PMid: 30808384 PMCid:PMC6390548

Baroncelli GI, Mora S. X-Linked hypophosphatemic rickets: Multisystemic disorder in children requiring multidisciplinary management. Frontiers in Endocrinology. 2021;12: 688309

https://doi.org/10.3389/fendo.2021.688309 PMid: 34421819 PMCid:PMC8378329

Trombetti A, Al-Daghri N, Brandi ML, Cannata-Andía JB, Cavalier E, Chandran M, et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nature Reviews Endocrinology. 2022; 18 (6):366-84. https://doi.org/10.1038/s41574-022-00662-x PMid:35484227

Rothenbuhler A, Schnabel D, Högler W, Linglart A. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism. 2020;103:153892. https://doi.org/10.1016/j.metabol.2019.03.009 PMid: 30928313

Laurent MR, De Schepper J, Godefroid N, Levtchenko E, Vande Walle J. Consensus recommendations for the diagnosis and management of X-linked hypophosphatemia in Belgium. Frontiers in endocrinology. 2021 Mar 19;12:641543. https://doi.org/10.3389/fendo.2021.641543 PMid: 33815294 PMCid: PMC8018577

Živičnjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U, et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatric Nephrology. 2011; 26:223-31.

https://doi.org/10.1007/s00467-010-1705-9 PMid: 21120538

Yakar S. Insulin-like growth factors: Actions 1 on the skeleton. J Mol Endocrinol 2018; 17‑0298. https://doi.org/10.1530/JME-17-0298

Živičnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R, et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab. 2011;96(12):E2097-105. https://doi.org/10.1210/jc.2011-0399 PMid:21994957

Seikaly MG, Brown R, Baum M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics. 1997; 100(5):879-84. https://doi.org/10.1542/peds.100.5.879 PMid:9346990

Haffner D, Nissel R, Wuhl E, Mehls O. Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics. 2004;113(6):e593-6.

https://doi.org/10.1542/peds.113.6.e593 PMid:15173542

Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr.2001;138(2):236-43. https://doi.org/10.1067/mpd.2001.108955 PMid: 11174622

Carpenter TO, Whyte MP, Imel EA, Boot AM, Högler W, Linglart A, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018; 378: 1987-98. https://doi.org/10.1056/NEJMoa1714641 PMid: 29791829

Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. The Lancet. 2019;393(10189):2416-27. https://doi.org/10.1016/S0140-6736(19)30654-3 PMid:31104833

Ertl DA, Le Lorier J, Gleiss A, Trabado S, Bensignor C, Audrain C, et al. Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone. Orphanet Journal of Rare Diseases. 2022;17(1):1-2. https://doi.org/10.1186/s13023-022-02562-9 PMid: 36371259 PMCid: PMC9652849

Smith S, Remmington T. Recombinant growth hormone therapy for X-linked hypophosphatemia in children. Cochrane Database Syst Rev. 2021; 10(10).https://doi.org/10.1002/14651858.CD004447.pub3 PMid: 34618915 PMCid:PMC8496964